Welcome Reception

Breakfast & Registration 

Welcome & introduction
Gareth Morgan & Ola Landgren 

Session 1A: Genomics and epigenomics 2026
Chairs: Gareth Morgan and TBC

Are NSD2 or MAF targets for therapy

• Mechanistic basis of NSD2 as an oncogene: Yubao Wang
• Apoptotic profiling of t(4:14) MM: TBC
• Epigenetic manipulation of NSD2of t(4;14) MM: Benjamin Barwick
• MAF: TBC

Discussion                                                                                                                   

Session 1B: Can we identify new prognostic factors and targets for therapy       
Chairs: Gareth Morgan and TBC

• Genetics and epigenetics of early myeloma: Mehmet Samur
• Structural variation in HR: Patrick Blaney
• Targeting structural variation by their detailed characterization: TBC
• Characterising breakout lesions to identify targets: TBC

Discussion                                                                                                                   

Break

Session 2: Targeting resistance mechanisms and HR biology
Chairs: TBC

• Epigenetic targets: TBC
• Epi drivers and drug resistance: Gareth Morgan
• Targeting superenhancers: TBC
• Overcoming resistance arising from target deletion: Nizar Bahlis
• Targeting p300: Charlotte Pawlyn

Panel discussion

Lunch

Session 3: Using biological models and single cell analyses to study drugs
Chairs: TBC

• Modeling resistance to T-cell therapies: TBC
• Using mouse models to find new targets: TBC
• Bone marrow organoids to evaluate therapies: Sarah Gooding
• CSF-1R inhibition & lenalidomide synergy in myeloma post ASCT: TBC
• Targeting the immune microenvironment: TBC

Panel discussion: Future strategies for myeloma management

Plenary Lecture
Epigenetic regulation of T cell echaustion in cancer: TBC
Chairs:  Ola Landgren & Gareth Morgan

Panel discussion

Break

Session 4: Integration of Clinical and Translational Research with the MMRF
Chairs: Hearn Cho & TBC

• Molecular correlates of Dara use in RRMM: TBC
• MM Immune Atlas: insights on NDMM and RRMM: TBC
• Horizon 2: a High Risk-NDMM adaptive platform trial: TBC

Panel Discussion

Closing Remarks for Day 1

Attendee Dinner

Welcome and Introductions Day 2

Session 5: Artificial intelligence in MM
Chairs: Ciara Freeman & TBC

• Potential power of AI in oncology: TBC
• Benefit AI in MM: Ciara Freeman
• Enhanced drug screening with AI: TBC
• AI in patient management: Ola Landgren              

Panel discussion 

Session 6: Therapy at 1-3 priors
Chairs: TBC                                                                          

• Tec-VRd:  TBC
• High-risk in the context TecDara: TBC
• Mechanism of action TecDara: TBC
• ADVANCE 2.0 trial: Dickran Kazandjian
• Cartitude-4: update: TBC
• Anito-cel:  TBC
• Isatuximab combinations: TBC

Panel discussion: Optimizing therapy choices at relapse

Break

Session 7: Optimizing T-Cell Engaging therapy

Part 1: Bispecifics and AV antibodies in MM
Chairs: Yi Lin & TBC

• Tal/Tec and their management: TBC
• CB-011:  TBC
• ABBV-383: TBC
• Trispecifics: TBC
• A role for BelaMaf: Hans Lee

Panel discussion: Optimizing the use of Bispecifics  & ADCs in the clinic 

Lunch

Part 2: CAR-T Management
Chairs: Adam Cohen & Ciara Freeman

• The role of Arlocel: TBC
• STEM study: Adam Cohen
• Managing neurotox and ALC expansion: TBC
• In vivo CAR-T designs: Yi Lin
• The role of anti CD19 binders in CAR-T constructs: TBC

Panel discussion: Optimizing the use of CAR-T in the clinic

Summary & closing remarks of iwMyeloma 2025

Gareth Morgan & Ola Landgren

iwMyeloma Scientific Committee: 

Gareth Morgan (Co-Chair) USA, Ola Landgren (Co-Chair) USA
Ken Anderson USA, Leif Bergsagel USA, Irene Ghobrial USA, Sagar Lonial USA, Maria Victoria Mateos Spain, Jesus San Miguel Spain, Pieter Sonneveld NL, Keith Stewart Canada